{"id":"r-da-epoch-21-auto-sct","safety":{"commonSideEffects":[{"rate":"20-50%","effect":"Neutropenia"},{"rate":"10-30%","effect":"Thrombocytopenia"},{"rate":"10-30%","effect":"Anemia"},{"rate":"5-20%","effect":"Infection"},{"rate":"5-15%","effect":"Febrile neutropenia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"The R-DA-EPOCH-21 regimen combines the monoclonal antibody rituximab with the EPOCH chemotherapy regimen, which includes etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin. The regimen is designed to target and eliminate cancer cells, followed by an autologous stem cell transplant to restore the patient's bone marrow.","oneSentence":"R-DA-EPOCH-21 is a chemotherapy regimen that combines rituximab with the EPOCH chemotherapy regimen, followed by an autologous stem cell transplant.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:31:05.229Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Diffuse large B-cell lymphoma"}]},"trialDetails":[{"nctId":"NCT03479918","phase":"PHASE3","title":"R-BL-M-04 Versus R-(DA)-EPOCH and Autologous Stem Cells Transplantation in Patients With High-Grade B-cell Lymphoma Double-hit (HGBL DH) and High-Grade B-cell Lymphoma Not Otherwise Specified (HGBL NOS)","status":"UNKNOWN","sponsor":"Elena N.Parovichnikova","startDate":"2018-03-15","conditions":"Lymphoma, High-Grade","enrollment":80},{"nctId":"NCT02842931","phase":"PHASE3","title":"R-Dose-adjusted (DA) - EPOCH-21 Versus R-modified Non-Hodgkin Lymphoma (NHL)-Berlin-Frankfurt-Munster (BFM)-90 Program (mNHL-BFM-90) and Autologous Stem Cells Transplantation (Auto-SCT) in DLBCL With Poor Prognosis","status":"UNKNOWN","sponsor":"National Research Center for Hematology, Russia","startDate":"2015-02","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":300}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["R-DA-EPOCH + auto-SCT"],"phase":"phase_3","status":"active","brandName":"R-DA-EPOCH-21 + auto-SCT","genericName":"R-DA-EPOCH-21 + auto-SCT","companyName":"National Research Center for Hematology, Russia","companyId":"national-research-center-for-hematology-russia","modality":"Small molecule","firstApprovalDate":"","aiSummary":"R-DA-EPOCH-21 is a chemotherapy regimen that combines rituximab with the EPOCH chemotherapy regimen, followed by an autologous stem cell transplant. Used for Diffuse large B-cell lymphoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}